Quisovalimab
As of the edition of 20 October 2026, Quisovalimab is an antibody: stopped in 2021; acts on TNFSF14.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Antibody
- Registered trials
- 3, 1 stopped early
- Disease areas
- Digestive system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Quisovalimab.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFSF14 | Tumor necrosis factor ligand superfamily member 14 | O43557 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Avalo Therapeutics | Lead sponsor of trials | 2017 to now |
| Aevi Genomic Medicine | Lead sponsor of trials | 2020 to now |